CD47 and glioblastoma: These optimized OMVs were then used to co‐deliver doxorubicin (DOX) and CD47 small interfering RNA (siCd47), which effectively reduced the phagocytosis escape ability of GBM cells, thereby enhancing the phagocytosis of GBM and overcoming the acquired immune resistance of GBM cells.[72]